Medifast(MED) - 2023 Q2 - Earnings Call Presentation

1 Q3 Guidance reflects continued customer acquisition challenges from the macro economic environment and GLP-1 drugs 2 Continue to invest in growth initiatives that are expected to benefit results in 2024 and beyond 3 Continue to reduce expenses through F4F initiative - optimization of procurement, distribution, co-manufacturing, and R&D activities 4 Launch of OPTAVIA ACTIVE™ product line in September to Customers will tap into a much larger addressable market than the current structured weight loss market ...